ZEB2 in T-cells and T-ALL. (December 2019)

• Record Type: Journal Article
• Authors: De Coninck, Stien; Berx, Geert; Taghon, Tom; Van Vlierberghe, Pieter; Goossens, Steven
• Is Part Of: Advances in biological regulation. Volume 74(2020)
• Publication Date: 2019-12
• Subjects: EMT -- ZEB2 -- T-cell acute lymphoblastic leukemia -- Cancer stem cells -- IL7R; Cellular control mechanisms -- Periodicals; Biological control systems -- Periodicals; Molecular biology -- Periodicals; Periodicals; 571.74
• DOI: 10.1016/j.jbior.2019.100639
• Languages: English
• ISSNs: 2212-4926

Abstract

Abstract: The identification of the rare but recurrent t(2; 14)(q22; q32) translocation involving the ZEB2 locus in T-cell acute lymphoblastic leukemia, suggested that ZEB2 is an oncogenic driver of this high-risk subtype of leukemia. ZEB2, a zinc finger E-box homeobox binding transcription factor, is a master regulator of cellular plasticity and its expression is correlated with poor overall survival of cancer patients. Recent loss- and gain-of-function in the mouse revealed important roles of ZEB2 during different stages of hematopoiesis, including the T-cell lineage. Here, we summarize the roles of ZEB2 in T-cells, their development, and malignant transformation to T-ALL.